New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma (LUMO) Reports Encouraging Interim Results from Two Phase 2 Trials of Oral LUM-201
-
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
-
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
-
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
-
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
-
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Lumos Pharma, Inc. (LUMO) Announces $3M Share Buyback
-
Lumos Pharma Announces Share Repurchase Program
-
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
-
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma, Inc. (LUMO) Enters Collaboration with Massachusetts General Hospital to Evaluate LUM-201
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
-
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
-
Form SC 13D/A LUMOS PHARMA, INC. Filed by: New Enterprise Associates 14, L.P.
-
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
-
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
-
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
-
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
-
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
-
Lumos Pharma to Participate in September Investor Conferences
-
Lumos Pharma to Participate in September Investor Conferences
-
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
